“Expert University” Course in Nanomedicine


Período: 01-29 July 2013

Biomedical Research Networking Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)

Room: CIBER-BBN, Barcelona Vigo

Time: Check with organisers

Speakers: Senior Researchers of the BIOCAPS project (IBIV)

Organises:  Biomedical Research Networking Centre on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)


In May 15 the period for enrollment Course Diploma in Nanomedicine opened. This is organized by the CIBER-BBN, in collaboration with the Open University and the National School of Health (ENS-ISCIII). This period is open until June 28.

All information is available in http://www.ciber-bbn.es/es/curso-nano

The registration can be done through this link: https://fundacionweb.uned.es/fundacionuned/simfun/

A press note is also attached.

more info >>>>

Master in Biological Sciences (MBS) at the University of Vigo, Spain


University of Vigo – Faculty of Biology

The main goal of the Master in Biological Sciences (MBS) is to provide graduate students with practical knowledge to take on top science‐based positions in Health and Environmental Sciences, Computational Biology and Biotechnology.

The official language of the MBS is English. Non‐ English speaking students must demonstrate a minimum of English proficiency (by holding a B1 certificate or through an oral interview). MBS aims to become an International Master Programme and to attract students of different nationalities.

More info >>>

EULAR 14th Annual European Congress of Rheumatology


The next EULAR Annual European Congress of Rheumatology will take place from 12-15 June 2013 in Madrid. Madrid 2013 will be a platform to facilitate interactions between patients, medical doctors, scientists, health professionals, and professionals representing the pharmaceutical industry both from within Europe and from around the world.

The EULAR Congress 2013 in Madrid will once again offer a wide range of topics including clinical innovations, clinical translational and basic science. In addition there will be meetings organised by people with arthritis, health professionals, and the health care industry. The central activity of the Congress will be poster presentations and poster tours with their highly interactive exchanges among participants. The Madrid event will further strengthen the reputation of the EULAR Congress as a highly innovative and informative venue for clinical and translational researchers not only within the different facets of our discipline (e.g., pain, bone, mechanical, and inflammatory disorders) but also for practising physicians who will find updated high-quality information on the management of diseases commonly seen in daily rheumatological practice.

Venue: Madrid

Speaker: Various

Organises:  European League Against Rheumatism (EULAR)

Link: http://www.eularcongressnews.eu/

Contact: Dr. Enrique Blázquez eblazquez@med.ucm.es

more info >>>>

X Curso para Postgraduados: “Fundamentos Moleculares de la Medicina


Dr. Enrique Blázquez from the Departament of Biochemistry and Molecular Biology, Faculty of Medicine (Universidad Complutense de Madrid) organises this course with the Support of the Fundación Lilly.

Information and registration: La información sobre las inscripciones (gratuitas), podrá encontrarla en el programa adjunto y las solicitudes deben dirigirse por correo electrónico a la atención del Prof. Enrique Blázquez, antes del 18 de mayo de 2013

Room: Sede de la Real Academia Nacional de Medicina

C/ Arrieta, 12; 28013 Madrid –  Ópera

Time: 10.00 hours

Speaker: Various

Organises:  Fundación Lilly

Contact: Dr. Enrique Blázquez eblazquez@med.ucm.es

more info >>>>

The Group of Immunology of the University of Vigo, new article in Plos One

The Group of Immunology of the University of Vigo has published the article “A Polymer/Oil Based Nanovaccine as a Single-Dose Immunization Approach” in Plos One.


The recognized necessity for new antigen delivery carriers with the capacity to boost, modulate and prolong neutralizing immune responses prompted our approach, in which we describe a multifunctional nanocarrier consisting of an oily nanocontainer protected by a polymeric shell made of chitosan (CS), named CS nanocapsules (CSNC). The CS shell can associate the antigen on its surface, whereas the oily core might provide additional immunostimulating properties. In this first characterization of the system, we intended to study the influence of different antigen organizations on the nanocarrier’s surface (using the recombinant hepatitis B surface antigen –rHBsAg– as a model antigen) on their long-term immunopotentiating effect, without any additional immunostimulant. Thus, two prototypes of antigen-loaded CSNC (CSNC+ and CSNC−), exhibiting similar particle size (200 nm) and high antigen association efficiency (>80%), were developed with different surface composition (polymer/antigen ratios) and surface charge (positive/negative, respectively). The biological evaluation of these nanovaccines evidenced the superiority of the CSNC+ as compared to CSNC- and alum-rHBsAg in terms of neutralizing antibody responses, following intramuscular vaccination. Moreover, a single dose of CSNC+ led to similar IgG levels to the positive control. The IgG1/IgG2a ratio suggested a mixed Th1/Th2 response elicited by CSNC+, in contrast to the typical Th2-biased response of alum. Finally, CSNC+ could be freeze-dried without altering its physicochemical properties and adjuvant effect in vivo. In conclusion, the evaluation of CSNC+ confirms its interesting features for enhancing, prolonging and modulating the type of immune response against subunit antigens, such as rHBsAg.

Citation: Vicente S, Diaz-Freitas B, Peleteiro M, Sanchez A, Pascual DW, et al. (2013) A Polymer/Oil Based Nanovaccine as a Single-Dose Immunization Approach. PLoS ONE 8(4): e62500. doi:10.1371/journal.pone.0062500

Editor: Prosper N. Boyaka, The Ohio State University, United States of America

Received: December 11, 2012; Accepted: March 21, 2013; Published: April 22, 2013

Copyright: © 2013 Vicente et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by a grant from the Bill and Melinda Gates Foundation (www.gatesfoundation.org), Consolider Ingenio 2010 CSD2006-00012 (Ministry of Science and Innovation, Spain) and Competitive Reference Groups SUDOE-FEDER (SOE1/P1/E014). SV and MP acknowledge a fellowship from the Spanish Ministry of Education (FPU predoctoral grants). DWP was in part supported by Montana Agricultural Experiment Station and US Department of Agriculture Formula Funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Link: more info


Resource: Group of Immunology of the University of Vigo.

Second Conference on Clinical Research with Private Centres


The Spanish Technology Platform for Innovative Medicines and FARMAINDUSTRIA are co-organizing, together with the Institute for Development and Integration of Health (IDIS), the Second Conference on Clinical Research with Private Centres, to be held on April 25 in the University Hospital Auditorium Quirón in Barcelona.

Registration must be made on-line at www.medicamentos-innovadores.org Attendance is free, but limited to the capacity of the room.


  • Amelia Martín Uranga
  • Farmaindustria
  • C/María de Molina, 54, 7ª – 28006 Madrid

Resource: Plataforma Tecnológica Española Medicamentos Innovadores, and FARMAINDUSTRIA.


1 23 24 25 26